Meet DOSUNMU ADEDOYIN OWOLABI, an Academic Staff of Lagos State University.
Haematology And Blood Transfusion Medicine
Associate Professor / Reader
Hematology and Blood Transfusion
At the Hematology And Blood Transfusion department office
Appointment on Visitation important
Topic: HAEMATO-ONCOLOGY
Description: 1. Institutional guidelines on management of haemato-oncology by systematic review of best of practices 2. Relevant clinical trials including association of viruses with haematological malignancies.3. Oncogenesis and application in haemato-oncology: application of targeted therapy in haematology practice4. Cell therapy: Application and study of cell therapy in oncology and sickle cell disease through partnership
| # | Certificate | School | Year |
|---|---|---|---|
| 1. | FELLOWSHIP EXAMINATION PART TWO PASSED (LABORATORY MEDICINE) | WEST AFRICAN COLLEGE OF PHYSICIANS | 1999 |
META ANALYSIS OF THE USE OF THE COMBINATION OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT NON HODGKIN S LYMPHOMAS
Indolent non Hodgkin&s lymphomas form about 70% of non Hodgkin&s lymphomas. They are characterized by early relapse 20% and refractory disease to immunochemotherapy. They are prevalent among the elderly who may not tolerate repeated chemotherapy and stem cell transplant.The aim of this analysis is to do a systematic analysis of clinical trials using meta analysis to determine the efficacy of this combination in indolent non Hodgkn&s disease.&span style= background-color: rgb 249, 249, 249 ; color: rgb 51, 51, 51 ; font-style: italic; font-weight: 400; &A systemic search of the data base of MEDLINE, COCHRANE and EMBASE was done and randomized controlled phase II/III trials were selected for review using the words: relapsed / refractory indolent lymphomas, clinical trials in follicular lymphoma, in small cell B cell lymphoma, in marginal zone lymphomas and secondary search with clinical trials with lenalidomide and rituximab.&/span&&span style= background-color: rgb 249, 249, 249 ; &&font color= #333333 &&span style= font-weight: 400; &&i&This analysis shall be with minimal bias and it is expected to help in developing our treatmentalgorithm for patients with relapsed/refractory disease since these agents are available in the country&/i&&/span&&/font&&/span&
DOSUNMU ADEDOYIN is a Associate Professor / Reader at the Department of Hematology and Blood Transfusion
DOSUNMU has a FELLOWSHIP EXAMINATION PART TWO PASSED in LABORATORY MEDICINE from WEST AFRICAN COLLEGE OF PHYSICIANS
